Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) has provided an update.
Oncopeptides AB announced that its drug Pepaxti has been included in the European guidelines for treating relapsed, refractory multiple myeloma, marking a significant recognition of its clinical value. This inclusion is expected to enhance Pepaxti’s awareness and usage across Europe, providing a crucial treatment option for patients with limited alternatives, and reflects the growing trust in its efficacy.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company focusing on research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company utilizes its proprietary Peptide Drug Conjugate platform to develop compounds that selectively deliver cytotoxic agents into cancer cells. Oncopeptides is commercializing its flagship drug in Europe and has partnership agreements in South Korea, the Middle East, and Africa. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 637,007
Current Market Cap: SEK362.5M
For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.